CareDx, Inc vs NeoGenomics, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- CareDx, Inc is the larger company by market value: $3.4 B against $2.2 B for NeoGenomics, Inc., 1.5 times as much (market caps of Oct 19, 2026 for CareDx, Inc and Oct 15, 2026 for NeoGenomics, Inc.).
- NeoGenomics, Inc. had more revenue: $727 M against $380 M for CareDx, Inc, both in the year to December 2025.
- Both made a net loss: $21 M for CareDx, Inc and $108 M for NeoGenomics, Inc.
- CareDx, Inc keeps more of each dollar of sales: a net margin of -5.6% against -14.9% for NeoGenomics, Inc.
- NeoGenomics, Inc. employs more people: 2,000 against 645 at CareDx, Inc. Each employee brings in about $588,837 of revenue at CareDx, Inc and $363,665 at NeoGenomics, Inc.
- CareDx, Inc's revenue grew faster in its latest fiscal year: +13.8% against +10.1% for NeoGenomics, Inc.
- Their Altman Z-scores put CareDx, Inc in the safe zone and NeoGenomics, Inc. in the grey zone.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | CareDx, Inc CDNA · #4,672 in the world | NeoGenomics, Inc. NEO · #6,041 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics and Research | Diagnostics and Research |
| Founded | 1998 | 2002 |
| Size | ||
| Market cap | $3.4 B | $2.2 B |
| Revenue | $380 M | $727 M |
| Net income | $-21 M▲ best | $-108 M |
| Employees | 645 | 2,000 |
| Valuation | ||
| P/E ratio | 26.1× | — |
| Price to sales | 6.8× | 2.8× |
| Price to book | 11.1× | 2.6× |
| Free cash flow yield | -0.2%▲ best | -1.0% |
| Profitability | ||
| Gross margin | — | 43.2% |
| Operating margin | -8.1%▲ best | -15.9% |
| Net margin | -5.6%▲ best | -14.8% |
| Return on equity | -6.3%▲ best | -12.4% |
| Growth | ||
| Revenue growth | 13.8%▲ best | 10.1% |
| Revenue growth, 3 years a year | 5.7% | 12.6%▲ best |
| Financial strength | ||
| Debt to equity | — | 0.4× |
| Cash | ||
| Free cash flow margin | — | -3.0% |
| Shareholder returns | ||
| Shareholder yield | 2.6% | — |
| Strength scores | ||
| Piotroski F-score | — | 4 of 9 |
| Altman Z-score zone | safe | grey |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, CareDx, Inc or NeoGenomics, Inc.?
CareDx, Inc is the larger company by market value: $3.4 B against $2.2 B for NeoGenomics, Inc., 1.5 times as much (market caps of Oct 19, 2026 for CareDx, Inc and Oct 15, 2026 for NeoGenomics, Inc.).
Which makes more money, CareDx, Inc or NeoGenomics, Inc.?
NeoGenomics, Inc. had more revenue: $727 M against $380 M for CareDx, Inc, both in the year to December 2025. Both made a net loss: $21 M for CareDx, Inc and $108 M for NeoGenomics, Inc.
Which is more profitable, CareDx, Inc or NeoGenomics, Inc.?
CareDx, Inc keeps more of each dollar of sales: a net margin of -5.6% against -14.9% for NeoGenomics, Inc.
Which has more employees, CareDx, Inc or NeoGenomics, Inc.?
NeoGenomics, Inc. employs more people: 2,000 against 645 at CareDx, Inc. Each employee brings in about $588,837 of revenue at CareDx, Inc and $363,665 at NeoGenomics, Inc.
Which is growing faster, CareDx, Inc or NeoGenomics, Inc.?
CareDx, Inc's revenue grew faster in its latest fiscal year: +13.8% against +10.1% for NeoGenomics, Inc.
Which is financially stronger, CareDx, Inc or NeoGenomics, Inc.?
Their Altman Z-scores put CareDx, Inc in the safe zone and NeoGenomics, Inc. in the grey zone.
More about CareDx, Inc
More about NeoGenomics, Inc.
Sources#
Every figure on this page comes from these, with the date shown next to it.